See Supplemental Patient Information
- Hypoglycemia is the most common adverse effect associated with insulin products. Severe hypoglycemia may lead to unconsciousness and/or convulsions and may result in temporary/permanent impairment of brain function or even death. It may result from excessive insulin dose, missed or reduced meal, or increased work or exercise without eating. Do not use in patients with pre-existing hypoglycemia
- Check blood sugar levels frequently and observe for signs of hypoglycemia in patients with diabetes
- Any change of insulin should be made cautiously and only under medical supervision. Changes in insulin strength, type, species, or method of manufacture may result in the need for a dosage change
- Hypokalemia may occur with the use of this product. Use cautiously in patients who are fasting, have autonomic neuropathy, or are using potassium-lowering drugs or in patients taking drugs sensitive to serum potassium level
- Dose adjustments may be required if there is any change in the patient's physical activity or their usual meal plan and also during illness, emotional disturbances, or other stress
- Lipodystrophy may occur following subcutaneous insulin administration; a planned rotation of sites within an area should be followed
- Local or serious systemic allergic reactions may occur with insulin administration. Provide immediate treatment in case of allergic reactions
- Regular monitoring of hemoglobin A1c is recommended for assessment of long-term glycemic control
- Concomitant use of thiazolidinediones can cause dose-related fluid retention, which may lead to or exacerbate heart failure. Monitor for signs and symptoms of heart failure and treat accordingly or consider discontinuation or dose reduction
Cautions: Use cautiously in patients with
- Renalimpairment
- Hepatic impairment
- Infection, stress, or illness
- Hypokalemia
Supplemental Patient Information
- Provide continued education and advice on regular glucose monitoring, insulin therapies, adherence to diet planning, timing of dose, complications of insulin therapy, life-style management, injection technique, periodic hemoglobin A1c testing, recognition and management of hypo- and hyperglycemia, and proper storage of insulin
- Inform patients that frequent, patient-performed blood glucose measurements are critical to achieve optimal glycemic control and avoid both hypo- and hyperglycemia and diabetic ketoacidosis
- Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to exercise caution when driving or operating machinery
- Instruct patients not to mix the product with any other insulin
- Advise patients to rotate subcutaneous injection sites and keep a record of sites used to help prevent fatty tissue breakdown
Pregnancy Category:B
Breastfeeding: No specific data available regarding the use of insulin lispro during breastfeeding. No adverse reactions have been reported due to insulin in breastmilk; infact, insulin in breastmilk may decrease the risk of type 1 diabetes in breastfed infants. In general, mothers with diabetes using insulin may nurse their infants. As per one study, insulin requirements are reduced postpartum in women with type I diabetes. The lower basal insulin requirement was thought to be caused by glucose use for milk production. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 5 March 2011). As per manufacturer's data, caution should be exercised when administering to a nursing woman. Women with diabetes who are breastfeeding may require adjustments of their insulin doses.
US Trade Name(s)
- Humalog Mix 50/50
- Humalog Mix 75/25
US Availability
Humalog Mix 50/50 (insulin lispro protamine/insulin lispro)
- INJ: [50 units/50 units]/mL (10 mL vial)
- Humalog KwikPen: [50 units/50 units]/mL (3 mL prefilled disposable injection device)
Humalog Mix 75/25 (insulin lispro protamine/insulin lispro)
- INJ: [75 units/25 units]/mL (10 mL vial)
- Humalog KwikPen: [75units/25 units]/mL (3 mL prefilled disposable injection device)
Canadian Trade Name(s)
- Humalog Mix 25
- Humalog Mix 50
Canadian Availability
Humalog Mix 25 (insulin lispro protamine/insulin lispro)
- INJ: [75 units/25 units]/mL (3 mL cartridges)
- Humalog Pen: [75 units/25 units]/mL (3 mL prefilled disposable injection device)
- Humalog KwikPen: [75units/25 units]/mL (3 mL prefilled disposable injection device)
Humalog Mix 50 (insulin lispro protamine/insulin lispro)
- INJ: [50 units/50 units]/mL (3 mL cartridges)
- Humalog KwikPen: [50 units/50 units]/mL (3 mL prefilled disposable injection device)
UK Trade Name(s)
- Humalog Mix 25
- Humalog Mix 50
UK Availability
Humalog Mix 25 (insulin lispro protamine/insulin lispro)
- INJ: [75 units/25 units]/mL (10 mL vial)
- INJ: [75 units/25 units]/mL (3 mL cartridges)
- Humalog KwikPen: [75units/25 units]/mL (3 mL prefilled disposable injection device)
Humalog Mix 50 (insulin lispro protamine/insulin lispro)
- INJ: [50 units/50 units]/mL (3 mL cartridges)
- Humalog KwikPen: [50 units/50 units]/mL (3 mL prefilled disposable injection device)
Australian Trade Name(s)
- Humalog Mix 25
- Humalog Mix 50
Australian Availability
Humalog Mix 25 (insulin lispro protamine/insulin lispro)
- INJ: [75 units/25 units]/mL (3 mL cartridges)
- Humalog KwikPen: [75units/25 units]/mL (3 mL prefilled disposable injection device)
Humalog Mix 50 (insulin lispro protamine/insulin lispro)
- INJ: [50 units/50 units]/mL (3 mL cartridges)
- Humalog KwikPen: [50 units/50 units]/mL (3 mL prefilled disposable injection device)
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- HumaLOG Mix 75/25 75-25 % SUSP [Vial] (LILLY)
10 % = $146.22
30 % = $409.01
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
